Two out of three ain’t bad, especially when the third is still in play. A hit in Phase III for Novartis AG’s second IgA nephropathy (IgAN) candidate, atrasentan, slots neatly next to the similar showing of iptacopan in the same disease disclosed at the start of the month.
Novartis Bookends October With Two IgAN Successes
A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.
More from Genitourinary
• By
Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.
• By
Gazyva could add the autoimmune condition to its label following a Phase III hit, but it might struggle to differentiate itself from Benlysta and Lupkynis.
• By
Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.
• By
The big pharma’s second selection in the alliance shows novel cardiovascular therapies are high on its priority list
More from Therapy Areas
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.